60 / 69
60
in patients with early and late chronic phase chronic
myeloid leukemia. Leuk Lymphoma 2008;49:2328-32.
45.
Scerni AC, Alvares LA, Beltrão AC, Bentes IR, Azevedo
TC, Bentes AQ, et al. Influence of late treatment on how
chronic myeloid leukemia responds to imatinib. Clinics
(Sao Paulo) 2009;64:731-4.
46.
Cortes JE, Talpaz M, Giles F, O'Brien S, Rios MB, Shan J, et
al. Prognostic significance of cytogenetic clonal evolution
in patients with chronic myelogenous leukemia on
imatinib mesylate therapy. Blood 2003;101:3794-800.
47.
Kantarjian HM, Cortes JE, O'Brien S, Luthra R, Giles F,
Verstovsek S, et al. Long-term survival benefit and
improved complete cytogenetic and molecular response
rates with imatinib mesylate in Philadelphia chromosome-
positive chronic-phase chronic myeloid leukemia after
failure of interferon-alpha. Blood 2004;104:1979-88.
48.
Palandri F, Iacobucci I, Martinelli G, Amabile M, Poerio A,
Testoni N, et al. Party on CML. Long-term outcome of
complete cytogenetic responders after imatinib 400 mg in
late chronic phase, philadelphia-positive chronic myeloid
leukemia: the GIMEMA Working Party on CML. J Clin
Oncol 2008;26:106-11.
49.
Gambacorti-Passerini C, Antolini L, Mahon FX, Guilhot F,
Deininger M, Fava C, et al. Multicenter independent
assessment of outcomes in chronic myeloid leukemia
patients treated with imatinib. J Natl Cancer Inst
2011;103:553-61.
50.
Fava C, Kantarjian HM, Jabbour E, O'Brien S, Jain N, Rios
MB, et al. Failure to achieve a complete hematologic
response at the time of a major cytogenetic response with
second-generation tyrosine kinase inhibitors is associated
with a poor prognosis among patients with chronic
myeloid leukemia in accelerated or blast phase. Blood
2009;113:5058-63.